 Home > Active Ingredient News > Blood System > Has the thrombosis problem after immunization with the COVID-19 recombinant vector vaccine been overcome?

Has the thrombosis problem after immunization with the COVID-19 recombinant vector vaccine been overcome?

 Last Update: 2021-06-06
 Source: Internet
 Author: User

Tags

brush cells

oxtellar side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compileriver

Recently, foreign media reported that researchers at the University of Frankfurt believe that they may have determined the cause of thrombosis after immunization with COVID-19 recombinant vector vaccines (such as AstraZeneca’s Vaxzevria and Janssen COVID-19 vaccines).

COVID-19 is a disease caused by the SARS-CoV-2 coronavirus.

According to preliminary studies, the rare coagulation events reported by these vaccines may be caused by the "vaccine-induced Covid-19 mimicry" syndrome (VIC19M syndrome).

The researchers also provided a possible explanation for why this coagulation occurred in recombinant vector vaccines rather than messenger RNA (mRNA) vaccines.

Reference source: Researchers may know the cause for COVID-19 vaccine related blood clots

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Has the problem of thrombosis after immunization with COVID-19 recombinant vector vaccine been overcome?

06-08

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Has the thrombosis problem after immunization with the COVID-19 recombinant vector vaccine been overcome?

Related Articles

Has the problem of thrombosis after immunization with COVID-19 recombinant vector vaccine been overcome?